tagitanlimab
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 15, 2025 (NCT07108816)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07109284 | Phase 2 | Sep 30, 2025 | Sichuan University |
| NCT07179783 | Phase 2 | Sep 22, 2025 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Tianjin Medical University |
| NCT07153965 | Phase 2 | Sep 1, 2025 | Tianjin Medical University |
| NCT07108816 | Phase 2 | Aug 15, 2025 | Henan Medical University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tianjin Medical University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 1 | 0 | 1 | 2025 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1